Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Doctors are increasingly using prescription drug monitoring programs — databases that track patients' drug history — in an effort to cut down on inappropriate opioid prescriptions. This corresponded with a 9% drop in opioid prescriptions between 2016 and 2017, according to new data from the American Medical Association.
What's next: The AMA says policymakers need to focus next on the barriers to treatment that people struggling with opioid addiction still face, including insurance coverage issues.
- "Treatment is key ... on average, 9 out of 10 patients who want access to medication assisted treatment can't get that medication assisted treatment," said Patrice Harris of the AMA's opioid task force.
Other key stats from the AMA's report:
- The number of opioid prescriptions decreased by 22% between 2013 and 2017.
- Prescriptions for naloxone – which is used for opioid overdose reversal — more than doubled in 2017 and are still on the rise in 2018.
- Over the past year, there's been a 42% increase in the number of providers certified to use buprenorphine to treat opioid use disorders.
Go deeper: The rise of newer, deadlier opioids; More people are blaming the opioid crisis on drug companies